A two-dose series of the vaccine was 100% effective against
COVID-19, measured seven days through over four months after the
second dose, the company said.
The long-term data will support planned submissions for
full-regulatory approval of the vaccine in the age group in the
United States and worldwide.
Pfizer and BioNTech will seek clearance for a 30 micrograms dose of
the vaccine for those aged 12 and above.
[to top of second column] |
The vaccine was authorized for
emergency use in people aged 12-15 years by the
U.S. Food & Drug Administration in May, and
granted full approval for use in people aged 16
and above in August.
(Reporting by Mrinalika Roy in Bengaluru;
Editing by Shinjini Ganguli)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |